HCW Biologics Inc (NASDAQ:HCWB) — Market Cap & Net Worth
Market Cap & Net Worth: HCW Biologics Inc (HCWB)
HCW Biologics Inc (NASDAQ:HCWB) has a market capitalization of $2.29 Million ($2.29 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29823 globally and #6005 in its home market, demonstrating a -6.78% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HCW Biologics Inc's stock price $1.10 by its total outstanding shares 6734104 (6.73 Million). Review HCWB current and long-term liabilities to assess the company's total debt and financial obligations.
HCW Biologics Inc Market Cap History: 2021 to 2026
HCW Biologics Inc's market capitalization history from 2021 to 2026. Data shows change from $15.62 Million to $7.41 Million (-29.90% CAGR).
Index Memberships
HCW Biologics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #884 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2807 of 3165 |
Weight: HCW Biologics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
HCW Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HCW Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
120.52x
HCW Biologics Inc's market cap is 120.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $15.62 Million | $4.10 Million | -$12.86 Million | 3.81x | N/A |
| 2022 | $12.90 Million | $6.72 Million | -$14.90 Million | 1.92x | N/A |
| 2023 | $8.25 Million | $2.84 Million | -$24.99 Million | 2.90x | N/A |
| 2024 | $3.00 Million | $2.57 Million | -$30.02 Million | 1.17x | N/A |
| 2025 | $6.54 Million | $54.23K | -$7.96 Million | 120.52x | N/A |
Competitor Companies of HCWB by Market Capitalization
Companies near HCW Biologics Inc in the global market cap rankings as of June 18, 2026.
Key companies related to HCW Biologics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
HCW Biologics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, HCW Biologics Inc's market cap moved from $15.62 Million to $ 7.41 Million, with a yearly change of -29.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.41 Million | +13.33% |
| 2025 | $6.54 Million | +117.57% |
| 2024 | $3.00 Million | -63.58% |
| 2023 | $8.25 Million | -36.03% |
| 2022 | $12.90 Million | -17.46% |
| 2021 | $15.62 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of HCW Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.29 Million USD |
| MoneyControl | $2.29 Million USD |
| MarketWatch | $2.29 Million USD |
| marketcap.company | $2.29 Million USD |
| Reuters | $2.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more